I would agree with the authors that given the lower risks of CAR T cell therapy that alloSCT has been pushed back in the treatment algorithm to post CAR T failure for DLBCL, FL, and MCL. It remains a highly effective option for PTCL relapsing post autoSCT and CLL refractory to BTKi and Venetoclax

Key Points
• The authors of the current article pondered the conventional role of alloHCT in light of the emergence of modern targeted molecular therapies and immunotherapies for B-cell lymphoma.
• “Although substantial therapeutic innovations in particular for B-cell lymphoma have entered the clinical stage recently, or are at the doorstep, immunotherapy by alloHCT remains an effective and potentially curative option for settings where the medical need unmet by traditional chemotherapy can also not be covered by novel therapeutics. This gap might be bigger than believed as some promises of novel agents given in phase-2 studies have not been fully kept in the real world,” the authors concluded.
• The following are standard indications for alloHCT, according to the authors.
Large B-cell lymphoma. 4th line after failure of induction, autoHCT attempt, and CAR T-cell therapy.
Follicular lymphoma. early relapse after salvage autoHCT or a similarly intensive regimen, and emerging exhaustion of hematopoiesis/incipient myelodysplasia.
Mantle cell lymphoma. 4th line after failure of induction, BTKi, and CAR T-cell therapy.
Peripheral T-cell lymphoma. relapsed/refractory disease.
• Importantly, the authors stressed that the window of opportunity for success of transplant is most substantial before tumor refractoriness and performance status deterioration have developed via serial palliative or experimental treatments.